APA (7th ed.) Citation

Mahlangu, J., Kaczmarek, R., von Drygalski, A., Shapiro, S., Chou, S., Ozelo, M. C., . . . Pipe, S. W. (2023). Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. The New England journal of medicine, 388(8), 694-705. https://doi.org/10.1056/NEJMoa2211075

Chicago Style (17th ed.) Citation

Mahlangu, Johnny, et al. "Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A." The New England Journal of Medicine 388, no. 8 (2023): 694-705. https://doi.org/10.1056/NEJMoa2211075.

MLA (9th ed.) Citation

Mahlangu, Johnny, et al. "Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A." The New England Journal of Medicine, vol. 388, no. 8, 2023, pp. 694-705, https://doi.org/10.1056/NEJMoa2211075.